Tag Archives: Novartis

Novartis puts AI on the job to help reps say the right things to the right doctors

SAN FRANCISCO—Artificial intelligence is a big buzzword in R&D right now, but at Novartis, it’s hard at work in the sales department, too. Amid far more meetings with digital companies at the J.P. Morgan Healthcare Conference this year, Novartis’ pharma CEO Paul Hudson said he expects 2019 to be the “beginning of the tech disruption” for… Read More »

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

SAN DIEGO—Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick. Sunday at the American Society of Hematology (ASH) annual meeting, Gilead’s Kite unit rolled out two-year data from the Zuma-1 study that won Yescarta its October 2017 approval… Read More »

Novartis abandons effort for U.S. approval of biosimilar rituximab

FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo (Reuters) – Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used… Read More »